Respiratory tract infection

Hologic to Acquire Mobidiag, Innovator in Near-Patient, Acute Care Diagnostic Testing, for Approximately $795 Million

Thursday, April 8, 2021 - 1:00pm

This includes a cash payment of approximately $714 million (600 million) for Mobidiags equity, and net debt of approximately $81 million.

Key Points: 
  • This includes a cash payment of approximately $714 million (600 million) for Mobidiags equity, and net debt of approximately $81 million.
  • Mobidiag develops and markets PCR (polymerase chain reaction)-based tests for acute care conditions such as gastrointestinal and respiratory infections, antimicrobial resistance management, and healthcare associated infections.
  • The Amplidiag and Novodiag platforms are automated instruments that deliver rapid turnaround times ranging from 50 minutes to two hours.
  • Mobidiag generated approximately $42 million (35 million) of revenue in calendar 2020.

Elder Berry Adulteration Documented by New Botanical Adulterants Prevention Program Article

Tuesday, March 23, 2021 - 5:03pm

Dietary supplements containing elder berry are widely used medicinally to treat symptoms of upper respiratory infections associated with colds and flus.

Key Points: 
  • Dietary supplements containing elder berry are widely used medicinally to treat symptoms of upper respiratory infections associated with colds and flus.
  • The elder berry adulteration article is the 64th peer-reviewed publication by BAPP, all of which are available for free access on the BAPP site .
  • To date, BAPP has published 64 peer-reviewed documents, including Botanical Adulterants Prevention Bulletins, Laboratory Guidance Documents, Botanical Adulterants Monitor e-newsletters, and others.
  • As with all of the programs publications, this review of elder berry adulteration is freely accessible on the programs website (registration required).

5th Annual Infection Control, Sterilization & Decontamination Conference: Two Day Online Conference - March 25th-26th, 2021 - ResearchAndMarkets.com

Thursday, February 25, 2021 - 1:22pm

The "5th Annual Infection Control, Sterilization & Decontamination Virtual Conference (GMT)" conference has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "5th Annual Infection Control, Sterilization & Decontamination Virtual Conference (GMT)" conference has been added to ResearchAndMarkets.com's offering.
  • Based on the survey on 1,000 hospitals in 33 countries, European Centre for Disease Prevention and Control (ECDC) estimates that that on any given day, one in 18 patients in a European hospital has a healthcare-associated infection (HAIs).
  • Most of the countries (26 out of 33) reported the major three types of HAIs: pneumonia and lower respiratory tract infection, surgical site infection, and urinary tract infection.
  • The 5th Annual Infection Control, Sterilization, and Decontamination in Healthcare Virtual Conference, scheduled for 25th & 26th March 2021, aiming at providing platform to experts from hospitals, academia, and government institutions discussing the innovations, challenges, and future aspects of infection control, decontamination, and sterilization.

Global Respiratory Infection Diagnostic Markets Report 2021-2025 with COVID-19 Impact, Forecasting/Analysis & Executive and Consultant Guides

Wednesday, January 27, 2021 - 4:45pm

DUBLIN, Jan. 27, 2021 /PRNewswire/ -- The "Respiratory Infection Diagnostic Markets by Technology, Plex, Place and by Region with COVID-19 Impact & Forecasting/Analysis, and Executive and Consultant Guides 2021-2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Jan. 27, 2021 /PRNewswire/ -- The "Respiratory Infection Diagnostic Markets by Technology, Plex, Place and by Region with COVID-19 Impact & Forecasting/Analysis, and Executive and Consultant Guides 2021-2025" report has been added to ResearchAndMarkets.com's offering.
  • The Multiplex factor is creating market confusion while lowering costs and improving care but important factors are holding back progress.
  • COVID-19 has broken open the market for point of care testing of respiratory infections.
  • The widespread nature of respiratory infections, (young people can get 8 colds a year) means that potential market sizes are enormous.

Respiratory Infection Diagnostic Markets, Analysis & Forecasting 2021-2025 by Technology, Plex, Place by Region and COVID-19 Impacts - ResearchAndMarkets.com

Tuesday, January 26, 2021 - 10:01am

The "Respiratory Infection Diagnostic Markets by Technology, Plex, Place and by Region with COVID-19 Impact & Forecasting/Analysis, and Executive and Consultant Guides 2021-2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Respiratory Infection Diagnostic Markets by Technology, Plex, Place and by Region with COVID-19 Impact & Forecasting/Analysis, and Executive and Consultant Guides 2021-2025" report has been added to ResearchAndMarkets.com's offering.
  • The Multiplex factor is creating market confusion while lowering costs and improving care but important factors are holding back progress.
  • COVID-19 has broken open the market for point of care testing of respiratory infections.
  • The widespread nature of respiratory infections, (young people can get 8 colds a year) means that potential market sizes are enormous.

Enanta Pharmaceuticals Announces the Appointment of John P. DeVincenzo, M.D. as Vice President of Translational Virology

Tuesday, January 5, 2021 - 12:01pm

as Vice President of Translational Virology.

Key Points: 
  • as Vice President of Translational Virology.
  • Johns appointment to this newly-created role reflects our commitment to advancing our RSV program and developing treatments for other respiratory infections, such as COVID-19 and human metapneumovirus.
  • His specialized experience in the development of RSV therapeutics will prove to be invaluable, and we are thrilled to welcome him to Enanta.
  • Enanta cautions investors not to place undue reliance on the forward-looking statements contained in this release.

AlloVir Announces FDA Clearance of Investigational New Drug Application for ALVR106, an Allogeneic, Off-the-Shelf, Multi-Virus Specific T Cell Therapy Targeting Four Devastating Respiratory Viruses

Thursday, December 17, 2020 - 12:30pm

The clearance of the IND for ALVR106 advances our third program into clinical trials further exploring the power of our proprietary virus-specific T cell therapy platform.

Key Points: 
  • The clearance of the IND for ALVR106 advances our third program into clinical trials further exploring the power of our proprietary virus-specific T cell therapy platform.
  • Respiratory tract infections due to RSV, influenza, PIV, and hMPV are a major public health concern and are detected in up to 40 percent of allogeneic HSCT patients.
  • AlloVir is a leading late clinical-stage cell therapy company with a focus on restoring natural immunity against life-threatening viral diseases in patients with weakened immune systems.
  • AlloVirs technology and manufacturing process enables the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy.

Global Respiratory Diseases Vaccine Market 2020-2025, by Infection, Type, Age Group and Geography and the Impact of COVID-19 with Ansoff Analysis - ResearchAndMarkets.com

Tuesday, December 8, 2020 - 11:23am

The "Global Respiratory Diseases Vaccine Market (2020-2025), by Infection, Type, Age Group and Geography and the Impact of Covid-19 with Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Respiratory Diseases Vaccine Market (2020-2025), by Infection, Type, Age Group and Geography and the Impact of Covid-19 with Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.
  • In addition to tobacco smoke, other risk factors include air pollution, occupational chemicals and dust, and frequent lower respiratory infections especially, children.
  • Chronic respiratory diseases (CRDs) are diseases of the airways and other structures of the lungs.
  • Treatments for each chronic Respiratory Diseases vary and the ideal solution is the reduction and avoidance of the stated risk factors.

NanoBio® Protect Teams Up with Good360 to Give Back to Frontline Workers and Communities in Need

Thursday, November 12, 2020 - 7:09pm

To achieve this, NanoBio Protect is launching an ongoing Buy 1 Give 1 philanthropic initiative.

Key Points: 
  • To achieve this, NanoBio Protect is launching an ongoing Buy 1 Give 1 philanthropic initiative.
  • For every bottle of NanoBio Protect purchased, BlueWillow will donate a bottle to frontline workers and families in high-risk communities nationwide through Good360.
  • In addition to masks and other PPE, once applied, NanoBio Protect provides an added layer of long-lasting protection to the nose from respiratory infection.
  • At its inception, more than 7,000 bottles of NanoBio Protect have already been donated to various frontline workers around the country, including medical professionals, and families in underprivileged communities.

OPKO Health's BioReference Laboratories Launches Multiplex COVID-19 and Influenza A/B Test

Tuesday, October 20, 2020 - 1:00pm

Differentiating COVID-19 and Influenza A or B infection(s) is especially important, as symptoms of COVID-19 and seasonal respiratory infections can be similar.

Key Points: 
  • Differentiating COVID-19 and Influenza A or B infection(s) is especially important, as symptoms of COVID-19 and seasonal respiratory infections can be similar.
  • BioReference offers a multiplex test for COVID-19 and Influenza Aand B, using a single sample.
  • The multiplex test may be performed on healthcare provider-collectednasaland nasopharyngeal swab specimens, and self-collected nasal swab specimens collected in a healthcare setting supervised by a healthcare provider.
  • "Patient care is at the center of our test offering and this multiplex test allows for healthcare providers to differentiate between COVID-19 and influenza by swabbing a patient one time."